Introduction {#s1}
============

Mutations in the adenomatous polyposis coli (*APC)* gene are responsible for Familial Adenomatous Polyposis (FAP), a genetic predisposition to colorectal cancer, and are also found in the majority of sporadic colonic tumors ([@bib14]). Critical roles for APC in colon carcinogenesis are attributed to its ability to negatively regulate the proliferative consequences of Wnt signaling through degradation of β-catenin, and maintain normal intestinal differentiation by controlling the biosynthesis of retinoic acid (RA) ([@bib21]; [@bib30], [@bib28], [@bib29]; [@bib33]; [@bib39]; [@bib40]). Although tremendous progress has been made in understanding the role of APC, its full battery of functions continue to expand.

Altered energy metabolism is an emerging hallmark in cancer ([@bib18]). The observation that cancer cells produce energy to support cell growth and proliferation differently than normal cells is known as the Warburg effect, and refers to neoplastic cells favoring aerobic glycolysis, even in the presence of ample oxygen ([@bib45]; [@bib46]). One of the major molecular mechanisms contributing to Warburg effect is mitochondrial dysfunction through impaired pyruvate metabolism ([@bib11]).

Pyruvate lies at the junction of glycolysis and the tricarboxylic acid (TCA) cycle. Contingent on the metabolic needs of the cell, pyruvate can be transported into the mitochondria, and through the action mainly of pyruvate dehydrogenase (PDH), it can be used to drive ATP production and generate building blocks for macromolecule biosynthesis through oxidative phosphorylation. Alternatively, pyruvate can be converted to lactate via lactate dehydrogenase (LDH) and exported out of the cell. Aberrations in genes involved in pyruvate metabolism and transport have been reported in human diseases, particularly in cancer ([@bib17]). For example, *monocarboxylate transporter 4 (MCT4)* and *LDHA* are overexpressed in cancer ([@bib22]; [@bib34]). An isoform of *pyruvate kinase 2 (PKM2)* is preferentially expressed in numerous cancer types including pancreatic, colon and lung, and has been shown to promote aerobic glycolysis in HeLa cells by functioning as a transcriptional coactivator for HIF-1 ([@bib7]; [@bib9]; [@bib23]; [@bib38]; [@bib49]). Restoration of the pyruvate dehydrogenase complex activity through inhibition of pyruvate dehydrogenase kinase 1 (PDK1) in head and neck squamous cell carcinoma cell lines led to reduced HIF-1a expression and tumor growth ([@bib25]).

The recently identified mitochondrial pyruvate carrier subunit *MPC1* is part of the MPC complex that is responsible for the uptake of pyruvate into the inner mitochondrial matrix ([@bib5]; [@bib19]). Recent work has revealed that *MPC1* is downregulated in various human cancers and that this correlates with poor survival ([@bib37]). Consistent with a causative role in tumorigenesis, re-expression of MPC1 repressed the Warburg effect in colon cancer cell lines ([@bib37]). It is not clear how MPC1 is regulated or how its activities relate to the known genetic events that contribute to colon cancer development. Given the potential role for MPC1 in colorectal cancer and the importance of APC mutation, we investigated the mechanistic relationship between the mutational status of *apc* and *mpc1*. Herein, we report that *apc* regulates pyruvate metabolism by controlling the levels of *mpc1* via RA. Further, *mpc1* is required and sufficient for initiating normal intestinal differentiation downstream of *apc*. Our findings strongly suggest that changes in metabolic profile can drive cell fate and differentiation decisions.

Results {#s2}
=======

*mpc1* and *mpc2* are downregulated in *apc*-deficient zebrafish {#s2-1}
----------------------------------------------------------------

To investigate the relationship between *apc* and *mpc*, we utilized the *apc^mcr^ *zebrafish, which is homozygous for a truncating mutation in the Mutation Cluster Region (MCR) of *apc* and similar to what is found in human colon tumors ([@bib20]; [@bib26], [@bib27]). In parallel, we also knocked down the expression of *apc* in wild type (WT) embryos using antisense morpholino (*apc* mo) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Evaluating gene expression of *mpc1* and *mpc2* by qRT-PCR, we found that both genes were significantly downregulated in *apc^mcr^* and *apc* mo embryos compared to WT/het siblings and control mo, respectively ([Figure 1A,B](#fig1){ref-type="fig"}). This was confirmed by whole mount in situ hybridization for *mpc1* and *mpc2* ([Figure 1C,D](#fig1){ref-type="fig"}). Additional in situ analyses for *mpc1* and *mpc2* in WT embryos revealed staining in the head, eyes, vasculature and somites at 24--48 hr post-fertilization (hpf) ([Figure 1E](#fig1){ref-type="fig"}). At later time points, expression in the pectoral fin buds, liver and gut emerged ([Figure 1E](#fig1){ref-type="fig"}). Cross sections of 72 hpf WT embryos previously probed with *mpc1* and *mpc2* confirmed gut expression for both genes (black arrows) ([Figure 1F](#fig1){ref-type="fig"}).10.7554/eLife.22706.003Figure 1.*mpc1* and *mpc2* are downregulated in *apc^mcr^* and *apc* morphant embryos.(**A**,**B**) Quantitative RT-PCR analysis of *mpc1* and *mpc2* gene expression in *apc^mcr^* (**A**) and *apc* mo (**B**) embryos. Values represent mean ± SD. Graph shown above is representative of at least three independent experiments. Statistical significance was analyzed using unpaired t-test. (**C**,**D**) Whole mount in situ hybridization for *mpc1* and *mpc2* in 72 hpf *apc^mcr^* (**C**) and *apc* mo (**D**) embryos. (**E**) Whole mount in situ hybridization for *mpc1* and *mpc2* in wild type (WT) embryos. head (h), eyes (e), somite (som), vasculature (vas), gut (g), liver (l). (**F**) Cross sections from 96 hpf WT embryos probed with either *mpc1* or *mpc2* confirmed gut-specific expression of both genes. See also [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22706.003](10.7554/eLife.22706.003)10.7554/eLife.22706.004Figure 1---source data 1.Fold change calculations for [Figure 1A,B](#fig1){ref-type="fig"}**DOI:** [http://dx.doi.org/10.7554/eLife.22706.004](10.7554/eLife.22706.004)10.7554/eLife.22706.005Figure 1---figure supplement 1.PCR analysis confirming *apc* knockdown.cDNA from 48 hpf embryos injected with either control (cont mo) or *apc* morpholino (*apc* mo) was used to amplify a 264 bp band corresponding to *apc* WT. A negative control with no reverse transcriptase (-) was also included. Amplification of 18s served as control for input cDNA (67 bp).**DOI:** [http://dx.doi.org/10.7554/eLife.22706.005](10.7554/eLife.22706.005)

Knock down of *mpc1* phenocopies *apc* knock down {#s2-2}
-------------------------------------------------

Previous studies have established phenotypes associated with impaired *apc* function in the developing zebrafish including malformation of the gut, eyes, pancreas and jaw, arrested fin buds and failed heart looping ([@bib28]; [@bib20]; [@bib31]). To determine whether loss of *mpc1* would recapitulate morphological defects related to *apc* deficiency, we knocked down the expression of *mpc1* in WT embryos with a splice-blocking morpholino which we confirmed by PCR ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Microinjection of 0.75 mM *mpc1* morpholino into WT embryos at the one- to two-cell stage resulted in about 87% of injected embryos appearing morphant (n = 228) ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Consistent with downregulation of *mpc1* in *apc^mcr^*, *mpc1* morphants (*mpc1* mo) exhibited a range of phenotypes consisting of smaller head and eyes, enlarged hindbrain vesicle (black arrows), pericardial edema, body curvature, and loss of pectoral fins (blue arrows) ([Figure 2A](#fig2){ref-type="fig"}).10.7554/eLife.22706.006Figure 2.Knock down of *mpc1* expression phenocopies loss of *apc*.(**A**) Gross phenotype associated with *mpc1* knock down. (**B**) Whole mount in situ hybridization analysis for organ-specific markers in *mpc1* mo. Alcian blue staining revealed improper cartilage development (\*) and confirmed loss of pectoral fins in *mpc1* mo. pectoral fin bud (pfb), heart (h), gut (g), pancreas (p). (**C**) Cross section of the eye and gut from control or *mpc1* mo. Prior to sectioning, embryos were previously stained with eye and gut-specific markers, *irbp* (red arrow) and *fabp2* (black arrow), respectively. (**D**) Co-injection with human *MPC1* RNA led to increased percentage of *mpc1* mo with normal pectoral fins as determined by in situ staining for *idi1*. Statistical significance was analyzed using Fisher's exact test. See also [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"}, [2](#fig2s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22706.006](10.7554/eLife.22706.006)10.7554/eLife.22706.007Figure 2---figure supplement 1.*mpc1* morphant phenotype is rescued by human *MPC1* RNA.(**A**) PCR analysis amplifying *mpc1* WT (322 bp) or morphant band (189 bp). Un-injected embryos (UI) served as a second control group. (**B**) Observed penetrance for *mpc1* morpholino. (**C**) Observed phenotype for *MPC1* mRNA overexpression in WT embryos. (**D**) Rescue of pectoral fins (pfb) and underdeveloped midbrain (mb) in 72 hpf *mpc1* mo co-injected with human *MPC1* RNA (*mpc1* mo + *MPC1* RNA) was determined by in situ hybridization for *id1* and *otx2*, respectively. (**E**) Quantification of embryos with normal midbrain and eye development as measured by *otx2* staining. Statistical significance was analyzed using Fisher's exact test. (**F**) PCR analysis confirming presence of human *MPC1* transcript (300 bp) in 48 hpf embryos.**DOI:** [http://dx.doi.org/10.7554/eLife.22706.007](10.7554/eLife.22706.007)10.7554/eLife.22706.008Figure 2---figure supplement 2.*mpc2* morphants phenocopy loss of *mpc1*.(**A**) Knockdown of *mpc2* expression in WT embryos (*mpc2* mo) resulted in phenotypes previously described for *mpc1* morphants including enlarged hindbrain (black arrows), body deformities and absence of pectoral fins (blue arrows). (**B**) PCR analysis using primers specific for amplifying *mpc2* WT (137 bp) or morphant band (1675 bp) confirmed knockdown of *mpc2* expression in 48 hpf embryos. (**C**) Observed penetrance for *mpc2* morpholino.**DOI:** [http://dx.doi.org/10.7554/eLife.22706.008](10.7554/eLife.22706.008)

In situ hybridization with *gata6* revealed that the primordial gut formed (93%, n = 55) in *mpc1* mo but developed abnormally, as shown by reduced staining for *fabp2* (100%, n = 36), which marks the differentiated gut ([Figure 2B](#fig2){ref-type="fig"}). Histological analyses on *mpc1* mo gut confirmed these findings, there were fewer cells comprising the gut tube and they appeared cuboidal and non-polarized ([Figure 2C](#fig2){ref-type="fig"}). Additionally, intestinal folds were visibly lacking in the *mpc1* mo gut (black arrow, [Figure 2C](#fig2){ref-type="fig"}). In contrast, cross-section of the gut from control mo showed polarized columnar intestinal cells, with the nuclei lined up clearly against the basal membrane ([Figure 2C](#fig2){ref-type="fig"}).

Since APC has also been reported to play a crucial role in congenital hypertrophy of retinal pigment epithelium (CHRPE) in humans and normal ocular development in the zebrafish embryo, we examined the eyes of *mpc1* mo and found that *irbp*, a marker for photoreceptor and retinal pigmented epithelial cells, was severely reduced in *mpc1* mo (95%, n = 40) ([Figure 2B](#fig2){ref-type="fig"}) ([@bib31]; [@bib8]). Cross-section of *mpc1* mo eye revealed small lens and disorganized cell layers ([Figure 2C](#fig2){ref-type="fig"}). The retinal cells appeared to be undifferentiated as supported by the loss of *irbp* expression (red arrow, [Figure 2C](#fig2){ref-type="fig"}).

Further phenotypic analyses of *mpc1* mo by in situ hybridization using tissue-specific markers exposed diminished maturation for brain (95%, n = 22) and fin buds (100%, n = 28) as indicated by *ascl1a* and *id1* expression, respectively ([Figure 2B](#fig2){ref-type="fig"}). Also, *mpc1* mo hearts failed to loop as determined by *myl7* staining (100%, n = 39) ([Figure 2B](#fig2){ref-type="fig"}). As with the gut, terminal differentiation of the pancreas in *mpc1* mo was severely reduced as assessed by *trypsin* expression, a marker for exocrine pancreas (100%, n = 28) ([Figure 2B](#fig2){ref-type="fig"}). *Insulin*, denoting the endocrine pancreas, remained normal (100%, n = 25) ([Figure 2B](#fig2){ref-type="fig"}). Cartilage staining with alcian blue confirmed the absence of pectoral fins and revealed improper jaw formation in *mpc1* mo (100%, n = 152) ([Figure 2B](#fig2){ref-type="fig"}).

We verified that the morphological defects we observed in *mpc1* mo were specifically due to knock down of *mpc1* by co-injecting with 0.5 ng of full length human *MPC1* mRNA and analyzing the embryos by in situ hybridization for *id1* and *otx2*, a marker for both the midbrain and eyes. Overexpression of *MPC1* mRNA alone resulted mostly in normal-appearing embryos, a small percentage exhibited cyclopia, severe body curvature and truncated tail (29%, n = 187) ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). However, in co-injected embryos (*mpc1* mo + *MPC1* RNA), we found that *MPC1* mRNA restored fin development as indicated by *id1* staining (50%, n = 49) ([Figure 2D](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}). We obtained similar results with *otx2*, *MPC1* mRNA was able to rescue normal midbrain and eye development in *mpc1* mo ([Figure 2---figure supplement 1D and E](#fig2s1){ref-type="fig"}). The presence of *MPC1* transcript was confirmed by PCR ([Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}).

*mpc1* and *mpc2* form a heterodimer complex that is responsible for transporting pyruvate from the inner mitochondrial space into the inner mitochondrial matrix ([@bib5]; [@bib19]). To examine whether loss of *mpc2* would result in similar phenotypes as *mpc1* mo, we knocked down its expression in WT embryos using antisense morpholino ([Figure 2---figure supplement 2A and B](#fig2s2){ref-type="fig"}). We found that *mpc2* mo exhibited similar developmental defects as *mpc1* mo, such as smaller head and eyes, enlarged hindbrain vesicle (black arrows), body curvature, and absence of pectoral fins (blue arrows) ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}). In contrast to *mpc1* mo, only a third of *mpc2* mo-injected embryos appeared morphant, the majority of which exhibited a mild phenotype ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}, [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}, data not shown). MPC2 expression is inconsistently altered in cancer and variably correlated with survival ([@bib37]). We therefore focused further studies on *mpc1*.

*MPC1* rescues intestinal differentiation in *apc*-deficient embryos {#s2-3}
--------------------------------------------------------------------

In light of our data relating reduced *mpc1* levels to failed intestinal differentiation, we sought to determine if re-expression of *MPC1* would rescue intestinal defects in *apc*-deficient zebrafish embryos. We injected 0.75 mM *apc* mo with or without 0.1 ng *MPC1* mRNA into WT embryos and evaluated intestinal differentiation by in situ hybridization for *fabp2*. Compared to *apc* mo (6%, n = 265), there was a significant increase in embryos with differentiated gut in the morpholino plus mRNA group (29%, n = 312) ([Figure 3A,C](#fig3){ref-type="fig"}). Control embryos all displayed normal *fabp2* expression (data not shown).10.7554/eLife.22706.009Figure 3.*MPC1* rescues gut phenotype of *apc mo* and *apc^mcr^*.(**A**,**B**) In situ hybridization for *fabp2*, in 72 hpf WT embryos injected with cont mo, *apc* mo or both *apc* mo and human *MPC1* RNA (*apc* mo + *MPC1* RNA) (**A**). In situ hybridization for *fabp2* in 72 hpf *apc* WT, *apc^mcr^* or *apc^mcr^* injected with human *MPC1* mRNA (*apc^mcr^* + *MPC1* RNA) (**B**). (**C**,**D**) Quantification of injected embryos with differentiated gut as determined by *fabp2* staining. Statistical significance was analyzed using Fisher's exact test.**DOI:** [http://dx.doi.org/10.7554/eLife.22706.009](10.7554/eLife.22706.009)

We confirmed this finding by injecting 0.5 ng *MPC1* mRNA into *apc^mcr^* and observed similar results, 40% of injected embryos re-expressed *fabp2* (n = 52) ([Figure 3B,D](#fig3){ref-type="fig"}). However, only 3% of un-injected *apc^mcr^* showed *fabp2* staining (n = 29), while WT/het siblings were all positive (n = 80, data not shown). *MPC1* was also able to rescue cardiac defects in *apc^mcr^*, as we saw improved blood circulation in injected mutants as well (data not shown). These results suggest that re-introduction of *mpc1* can drive intestinal differentiation.

Knock down of *mpc1* or *apc* alters mitochondrial function {#s2-4}
-----------------------------------------------------------

Because of the integral role of MPC1 in pyruvate metabolism, we next investigated if *mpc1* mo harbor metabolic defects as a consequence of diminished *mpc1* function. We assessed mitochondrial respiration by measuring oxidative consumption rates (OCR) in 72 hpf embryos and there was a significant reduction in OCR in *mpc1* mo compared to control ([Figure 4A](#fig4){ref-type="fig"}). We also looked at triglyceride (TG) levels as an indicator of disturbance in normal energy utilization and observed a similar trend ([Figure 4B](#fig4){ref-type="fig"}). Moreover, there was an extensive dysregulation of pyruvate metabolism upon loss of *mpc1*, as we discovered a profound upregulation of pyruvate metabolic genes in *mpc1* mo, suggesting a compensatory mechanism to account for reduced pyruvate transport across the inner mitochondrial membrane ([Figure 4---figure supplement 1A and B](#fig4s1){ref-type="fig"}). Knock down of *mpc2* did not affect *mpc1* transcript level ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}).10.7554/eLife.22706.010Figure 4.Knock down of *mpc1* or *apc* leads to altered mitochondrial respiration and pyruvate metabolism.(**A**) Mitochondrial respiration was evaluated by measuring oxygen consumption rates (OCR) in 72 hpf embryos. (**B**) Triglyceride (TG) levels were determined in lysates prepared from 72 hpf embryos using a colorimetric assay. (**C**,**D**) Quantitative RT-PCR analysis of enzymes involved in pyruvate metabolism in *apc* mo and (**C**) *apc^mcr^* (**D**) embryos. *pyruvate dehydrogenase alpha 1a (pdha1a); pyruvate dehydrogenase kinase, isozyme 1 (pdk1); pyruvate kinase, muscle, a (pkma); citrate synthase (cs)*. (**E**) Lactate levels in *apc* wild type (WT), un-injected *apc^mcr^* (UI) or *apc^mcr^* embryos injected with human *MPC1* mRNA (MPC1 RNA). For figures **A--E**, values represent mean ± SD. Graph shown above is representative of at least three independent experiments. Statistical significance was analyzed using unpaired t-test. (**F**,**G**,**H**) Gross phenotype (**F**), alcian blue staining (**G**) and in situ hybridization for *fabp2* (**H**) in *pdha1a*, *pcxb*, and *pcxb* + *pdha1a* mo. *pcxb (pyruvate carboxylase b).* See also [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"}, [2](#fig4s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22706.010](10.7554/eLife.22706.010)10.7554/eLife.22706.011Figure 4---source data 1.Mean and standard deviation values for [Figure 4A,B,E](#fig4){ref-type="fig"}; fold change calculations for [Figure 4C,D](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22706.011](10.7554/eLife.22706.011)10.7554/eLife.22706.012Figure 4---figure supplement 1.Knockdown of *mpc1* leads to dysregulated pyruvate metabolism.(**A**) A simplified scheme showing key enzymes (in blue) involved in pyruvate transport and metabolism (adapted from [@bib36]). (**B**) Quantitative RT-PCR analysis of pyruvate metabolism enzymes in *mpc1* mo. (**C**) Quantitative RT-PCR analysis of *mpc1* in *mpc2* mo. For **B--C**, values represent mean ± SD. Graph shown above is representative of at least three independent experiments. Statistical significance was analyzed using unpaired t-test. *pyruvate dehydrogenase alpha 1a (pdha1a); pyruvate carboxylase b (pcxb); lactate dehydrogenase A4 (ldha); pyruvate dehydrogenase kinase, isozyme 1 (pdk1); citrate synthase (cs); solute carrier family 16, member 1 (slc16a1); solute carrier family 16, member 3 (slc16a3); pyruvate kinase, muscle, a (pkma); mitochondrial pyruvate carrier 2 (mpc2)*.**DOI:** [http://dx.doi.org/10.7554/eLife.22706.012](10.7554/eLife.22706.012)10.7554/eLife.22706.013Figure 4---figure supplement 1---source data 1.Fold change calculations for [Figure 4---figure supplement 1B,C](#fig4s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22706.013](10.7554/eLife.22706.013)10.7554/eLife.22706.014Figure 4---figure supplement 2.PCR analysis confirming knockdown of *pdha1a, pcxb*.(**A**,**B**) cDNA from 48 hpf embryos injected with cont mo, *pcxb* mo or *pdha1a* mo was used to amplify a band corresponding to *pcxb* WT (355 bp) (**A**) or *pdha1a* WT (254 bp) (**B**). A negative control with no reverse transcriptase (-) was also included. Amplification of 18s served as control for input cDNA (67 bp). (**C**) Microinjection of WT embryos with *pdha1a* morpholino (*pdha1a* mo) resulted in a higher penetrance compared to *pcxb* morpholino (*pcxb* mo). Co-injection of both morpholinos gave the highest percentage of embryos with phenotype (*pcxb* mo + *pdha1a* mo).**DOI:** [http://dx.doi.org/10.7554/eLife.22706.014](10.7554/eLife.22706.014)

Earlier studies have reported that *MPC1* is downregulated in colon cancer and its expression positively correlates with *APC* ([@bib37]). Together with our previous data showing that *mpc1* is downregulated in *apc*-deficient zebrafish and that *mpc1* mo exhibit impaired oxidative respiration, we hypothesized that *apc* regulates *mpc1* and therefore, pyruvate metabolism overall. To test this, we evaluated mitochondrial respiration and TG levels in *apc^mcr ^*and *apc* mo and compared to appropriate controls, we observed significant defects in mitochondrial function upon loss of *apc* ([Figure 4A,B](#fig4){ref-type="fig"}). Several enzymes in the pyruvate pathway were also differentially regulated in *apc^mcr^* or *apc* mo ([Figure 4C,D](#fig4){ref-type="fig"}).

To further validate that impaired mitochondrial function in *apc^mcr ^*is facilitated by reduced *mpc1* expression, we injected *MPC1* mRNA into *apc* mutant embryos and looked at lactate levels as indicator of improved mitochondrial function. Compared to un-injected *apc^mcr^*, mutant embryos overexpressing *MPC1* showed a significant reduction in lactate ([Figure 4E](#fig4){ref-type="fig"}). *apc* WT/het sibs (WT) represent basal lactate levels in normal embryos ([Figure 4E](#fig4){ref-type="fig"}).

Pyruvate, after passing through the inner mitochondrial membrane, is converted to oxaloacetate and acetyl-CoA by pyruvate carboxylase (PC) and pyruvate dehydrogenase (PDH), respectively. To ascertain if the knock down of enzymes downstream of *mpc1* would result in a phenotype similar to *mpc1* mo, we targeted *pcxb* and *pdha1a*, separately and in tandem, with antisense morpholinos ([Figure 4---figure supplement 2A and B](#fig4s2){ref-type="fig"}). Loss of either metabolic gene or both, resulted in morphant embryos that lacked pectoral fins (blue arrows), jaw (red arrows) and appeared identical to *mpc1* mo ([Figures 4F--H](#fig4){ref-type="fig"}, [2A](#fig2){ref-type="fig"}). Interestingly, knock down of *pcxb* resulted in only 22% of embryos with phenotype (n = 27) while targeting *pdha1a* gave a higher percentage of morphant embryos (63%, n = 19) ([Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}). A synergistic effect was observed when both enzymes were diminished (83%, n = 18) ([Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}). *fabp2* in situ staining (black arrows) also revealed intestinal developmental defects in the *pdha1a* mo*, pcxb* mo and *pdha1a + pcxb* morphant embryos ([Figure 4H](#fig4){ref-type="fig"}). Knock down of *pcxb* expression, however, not only resulted in low penetrance but mild phenotype as well ([Figure 4F--H](#fig4){ref-type="fig"}). This could be due to the activation of an alternative pathway where oxaloacetate can be derived from glutamine instead of pyruvate ([@bib10]).

Decreased RA levels lead to aberrant pyruvate metabolism {#s2-5}
--------------------------------------------------------

To further elucidate how *apc* is controlling *mpc1*, we initially looked at Wnt signaling as one of the major roles of APC is to regulate degradation of β-catenin ([@bib14]). Perturbation of the Wnt pathway by treatment of *apc* mo with 10 uM NS-398, a COX-2-specific inhibitor that has been shown to impair β-catenin activity in an *apc*-deficient background, did not affect *mpc1* or *mpc2* levels ([Figure 5A](#fig5){ref-type="fig"}) ([@bib13]). We did see a dramatic reduction in expression of known β-catenin target gene, *mmp9*, implying that *apc* regulation of *mpc1* is independent of Wnt ([Figure 5A](#fig5){ref-type="fig"}).10.7554/eLife.22706.015Figure 5.RA deficiency results in dysregulated pyruvate metabolism that is independent of Wnt pathway.(**A**) *apc* mo treated either with DMSO control or 10 uM NS-398 were analyzed by qRT-PCR to determine expression levels of *mpc1*, *mpc2* and *mmp9*. (**B**,**C**) WT embryos treated with either DMSO control or 5 uM DEAB were analyzed by qRT-PCR to determine expression levels of enzymes involved in pyruvate metabolism. (**D**) Lactate levels in 72 hpf WT embryos treated with either DMSO or 5 uM DEAB. For figures **A--D**, values represent mean ± SD. Graph shown above is representative of 3 independent experiments. Statistical significance was analyzed using unpaired t-test. *matrix metallopeptidase 9 (mmp9); solute carrier family 16, member 1 (slc16a1).*.**DOI:** [http://dx.doi.org/10.7554/eLife.22706.015](10.7554/eLife.22706.015)10.7554/eLife.22706.016Figure 5---source data 1.Fold change calculations for [Figure 5A,B,C](#fig5){ref-type="fig"}; mean and standard deviation values for [Figure 5D](#fig5){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22706.016](10.7554/eLife.22706.016)

In addition to regulating Wnt signaling, *apc* controls the program of intestinal differentiation through regulation of RA levels, as we have previously shown ([@bib21]; [@bib30], [@bib28], [@bib29]; [@bib33]; [@bib40]). To interrogate the involvement of RA in pyruvate metabolism downstream of *apc*, we treated WT embryos with DMSO or 5 uM DEAB, a known inhibitor of RALDH which catalyzes the second step in the conversion of Vitamin A to the active metabolite, RA ([@bib24]; [@bib35]). By qRT-PCR, we found that *mpc1* and *mpc2* transcript levels went down significantly with inhibition of RA ([Figure 5B](#fig5){ref-type="fig"}). Expanding our analyses to include other components of pyruvate metabolism, there were five other genes that were either up- or downregulated upon DEAB treatment, supporting the notion that the pyruvate metabolic program is altered at various points when RA levels are perturbed ([Figure 5C](#fig5){ref-type="fig"}). The DEAB-treated embryos also had low lactate levels, further establishing that RA inhibition results in mitochondrial dysfunction ([Figure 5D](#fig5){ref-type="fig"}).

Pyruvate metabolism is dysregulated in colon cancer {#s2-6}
---------------------------------------------------

To further understand the implication of our findings in zebrafish, we employed publicly available curated databases to investigate mutations and gene expression alterations of pyruvate metabolism genes in human cancers. Using samples deposited at The Cancer Genome Atlas (TCGA), we selected for colon adenocarcinomas with mutations upstream of codon 1600 of APC, a region encompassing the MCR, and resulting in a truncated protein similar to those found in a majority of patients with FAP ([@bib14]). Consistent with our previous data, we found that *mpc1* expression is significantly downregulated in colon adenocarcinomas with APC deletions (n = 91) compared to normal colon (n = 19) ([Figure 6A](#fig6){ref-type="fig"}). We also looked at other genes involved in pyruvate transport and metabolism and interestingly, MPC1, MPC2, PDHA1 and PC showed consistent downregulation in a specific subset of colon adenocarcinomas known as colon mucinous adenocarcinomas (AC) (n = 22) ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). In addition to altered gene expression, we also found colorectal cancer samples in COSMIC that had mutations both in APC and pyruvate metabolism enzymes. There were five samples with somatic APC deletions that had mutations in multiple pyruvate metabolism enzymes as well, most of which are predicted to be probably (\*\*) or possibly (\*) damaging, further supporting a genetic link between APC mutation and dysregulation of pyruvate metabolism ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}).10.7554/eLife.22706.017Figure 6.In silico analyses of *APC* and pyruvate metabolism gene alterations in cancer.(**A**) *MPC1* expression levels in TCGA normal colon and colon adenocarcinoma samples harboring truncating mutations in APC upstream of codon 1600. Statistical significance was analyzed using Mann Whitney test. (**B**) ONCOMINE database was analyzed for gene expression alterations in pyruvate metabolism genes in all cancer types. A control group composed of Uniprot random genes was used for comparison. Graph shows percentage of up- and downregulated genes with respect to the total unique analyses for each gene tested for all cancer groups. Statistical significance was analyzed using Mann Whitney test. (**C**) cBioportal analysis to estimate Kaplan-Meier overall survival of TCGA colorectal adenocarcinoma and kidney chromophobe patients with or without alterations in pyruvate metabolism (PM) genes. For **B--C**, pyruvate metabolism genes used in meta-analyses: *MPC1, MPC2, CS, PDK1, PDHA1, PC, PKLR, LDHA, SLC16A1, GYS1*. See also [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, [Supplementary files 1](#SD5-data){ref-type="supplementary-material"}, [2](#SD6-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22706.017](10.7554/eLife.22706.017)10.7554/eLife.22706.018Figure 6---figure supplement 1.Pyruvate metabolism genes are mutated in human colon carcinomas.(**A**) Gene expression levels of pyruvate metabolism genes in TCGA normal colon and colon mucinous adenocarcinoma (MA). Statistical significance was analyzed using Mann Whitney test. (**B**) Colon carcinomas harboring APC mutations were identified from the COSMIC database. Of the 35 samples that were found, five had multiple mutations in pyruvate metabolism genes that are predicted to be at least possibly damaging based on Polyphen2 in silico protein analysis. (\*\*\*) -- deletion; Polyphen2 prediction: (\*\*) -- probably damaging, (\*) -- possibly damaging, (*italics*) -- benign.**DOI:** [http://dx.doi.org/10.7554/eLife.22706.018](10.7554/eLife.22706.018)

Several studies have shown that individual genes in the pyruvate metabolism pathway are altered in various cancer types ([@bib17]; [@bib37]). Using Oncomine, we extended these studies by treating the genes involved in pyruvate transport and metabolism as a group (n = 10). We discovered that this pathway is significantly dysregulated in cancer compared to a group of randomly-generated Uniprot genes (n = 55) ([Figure 6B](#fig6){ref-type="fig"}, [Supplementary file 1](#SD5-data){ref-type="supplementary-material"}). We then looked at overall survival for patients, with or without mutations and/or gene expression changes in the pyruvate metabolism gene set using TCGA samples in cBioportal. Out of 21 cancer types that we analyzed, only colorectal adenocarcinoma and kidney chromophobe carcinoma showed a significant difference in overall survival between the two groups ([Figure 6C](#fig6){ref-type="fig"}, [Supplementary file 2](#SD6-data){ref-type="supplementary-material"}).

Discussion {#s3}
==========

Recent identification of *MPC1* and *MPC2*, genes responsible for pyruvate uptake into the mitochondrial matrix, has added a new complexity to targeting pyruvate metabolism in human disorders, including cancer ([@bib17]; [@bib5]; [@bib19]). How dysregulation of metabolism relates to the accumulation of genetic hits that cause tumor suppression has largely been unstudied. Here, we demonstrate a direct relationship between loss of a key tumor suppressor gene, *APC*, and dysregulation of *MPC1*. Our finding that *mpc1* expression is downregulated in embryos harboring a genetic mutation (*apc^mcr^*) or knocked down expression (*apc mo*) of *apc* is reflected in human tumors as well, where we not only discovered a significant downregulation of *MPC1* expression in colon adenocarcinomas with APC deletions, but also samples possessing mutations in both APC and several pyruvate metabolism enzymes ([Figure 1](#fig1){ref-type="fig"}, [Figure 6](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Our meta-analyses of human cancer data sets also revealed extensive dysregulation of pyruvate metabolism, at multiple points in the pathway, and this incidence of altered gene expression of pyruvate metabolism genes in cancer is significantly more prevalent compared to a group of randomly selected genes ([Figure 6](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, [Supplementary file 1](#SD5-data){ref-type="supplementary-material"}). It is remarkable how *MPC1* and *MPC2*, *PDHA1* and *PC*---genes that are involved in the transport and conversion of pyruvate in the inner mitochondrial matrix, respectively---are all significantly downregulated in a subset of colon adenocarcinomas categorized as colon mucinous adenocarcinomas, as loss of these genes essentially shuts down oxidative phosphorylation in the mitochondria ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Interestingly, additional in silico analyses suggest a potential use of pyruvate metabolism genes as prognostic markers for colorectal adenocarcinoma and kidney chromophobe carcinoma, as we found a strong correlation between aberrations in pyruvate metabolism genes with poor overall survival in these cancer types ([Figure 6](#fig6){ref-type="fig"}).

It is interesting to note that there are differences in the dysregulation of pyruvate metabolism genes in *apc^mcr^*/*apc mo* and *mpc1 mo* ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). APC is a multifunctional protein that has critical roles in various cellular processes ([@bib15]). In addition, regulation of other metabolic genes by APC could occur in parallel with regulation of *mpc1. mpc1* knock down alone, therefore, would not alter the expression of these genes in the same way as knock down of *apc*. Confirming a functional epistatic relationship between *apc* and *mpc1*, knock down of *mpc1* in WT embryos resulted in phenotypes that have been previously reported for impaired *apc* function ([Figure 2](#fig2){ref-type="fig"}) ([@bib28]; [@bib20]). APC has been shown to positively regulate glycogen synthase kinase-3 (GSK-3) activity, an enzyme that inhibits glycogen synthase (GS) which is involved in converting glucose into glycogen for storage ([@bib3]; [@bib44]). Taken together, these findings suggest a major role for APC in controlling cellular bioenergetics and homeostasis, as it can affect glycogen synthesis and oxidative phosphorylation through GSK-3 and MPC1, respectively.

The exact role of metabolism in cancer as a driver versus passenger process has been unclear. Indeed, roles for metabolism in directing cell fate and differentiation decisions are only now being considered ([@bib37]; [@bib4]; [@bib41]; [@bib48]; [@bib50]). The rescue of intestinal differentiation defects in embryos with impaired *apc* function by exogenous *MPC1* mRNA establishes a clear role for metabolic programming as a switch that can control cell fate decisions ([Figure 3](#fig3){ref-type="fig"}). Mechanistic insights into regulatory pathways that control metabolism and how perturbations in cellular bioenergetics effect cell differentiation and proliferation can lead to a better understanding of normal development and tumorigenesis. In this respect, the role of retinoic acid in promoting cell fate and differentiation remains undefined. Our studies suggest that RA may control a program of metabolism that is permissive for intestinal differentiation. The actions of RA are complex, and it is likely that the effects of RA on metabolism are indirect. Consistent with this, treatment of either WT or *apc^mcr^* embryos with RA did not result in an immediate induction of *mpc1* (data not shown).

To conclude, we present a novel role for *apc* in controlling a metabolic program driving intestinal differentiation through regulation of *mpc1*. Our data strongly support the notion that metabolic changes are a major part of the decision process in determining cell fate and provide a better understanding of how cancer genetics is linked with biochemical metabolic pathways.

Materials and methods {#s4}
=====================

Zebrafish maintenance {#s4-1}
---------------------

Wild-type (WT) *TU* (RRID:[ZIRC_ZL57](https://scicrunch.org/resolver/ZIRC_ZL57)) and *apc^WT/mcr^* (RRID:[ZFIN_ZDB-ALT-050914-2](https://scicrunch.org/resolver/ZFIN_ZDB-ALT-050914-2)) Danio *rerio* (zebrafish) were maintained as previously described ([@bib47]). Fertilized embryos were collected following natural spawnings in 1 × E3 medium (286 mg/L NaCl, 13 mg/L KCl, 48 mg/L CaCl~2~·2H~2~O, 40 mg/L MgSO~4~, 0.01% methylene blue) and allowed to develop at 28.5°C.

Morpholino and RNA microinjections {#s4-2}
----------------------------------

Morpholino oligonucleotides were obtained from Gene Tools LLC (Philomath, OR) and solubilized to 1 mM or 3 mM stock solutions in 1x Danieau buffer. For microinjections, 1 nl of morpholino was injected into WT embryos at the 1- to 2-cell stages ([@bib12]). Knock down of gene expression was assessed by PCR. Primers were designed according to guidelines recommended by Gene Tools ([www.gene-tools.com](http://www.gene-tools.com)) to amplify WT and splice-blocked morphant bands. *z18s* was amplified as a control gene.

For RNA rescue experiments, full length human RNA transcripts were transcribed from linearized DNA using mMESSAGE mMACHINE transcription kit (Ambion - Waltham, MA). For microinjections, 1--2 nl of RNA was injected into embryos at the 1- to 2-cell stages. Overexpression of mRNA transcript was assessed by PCR. Statistical analyses were performed using Fisher's exact test (GraphPad Prism v 6.04, RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)).

A complete list of morpholinos, PCR primers and working concentrations used are provided in [Supplementary files 3](#SD7-data){ref-type="supplementary-material"}--[4](#SD8-data){ref-type="supplementary-material"}.

Zebrafish drug treatments {#s4-3}
-------------------------

Wild type embryos were given DEAB (VWR International - Radnor, PA) at 5 µM. *apc* morphants were treated with 10 µM NS398 (Cayman Chemical - Ann Arbour, MI). Embryos were harvested at 72 hpf in RNAlater (Ambion) for RNA/cDNA prep.

In situ hybridization {#s4-4}
---------------------

In situ hybridizations were performed as previously described using digoxigenin-labeled riboprobes for *ascl1a (achaete-scute family bHLH transcription factor 1a)*, *fabp2 (fatty acid binding protein 2, intestinal)*, *gata6 (GATA binding protein 6)*, *id1 (inhibitor of DNA binding 1)*, *insulin*, *irbp (interphotoreceptor retinoid-binding protein)*, *mpc1 (mitochondrial pyruvate carrier 1)*, *mpc2 (mitochondrial pyruvate carrier 2)*, *myl7 (myosin, light chain 7, regulatory)*, *otx2 (orthodenticle homeobox 2)* and *trypsin* ([@bib43]). Embryos were cleared in 2:1 benzyl benzoate/benzyl alcohol solution and documented using an Olympus SZX12/DP71 imaging system (Olympus Corporation - Japan). RNA Reference Sequences deposited in ZFIN (zfin.org, RRID:[SCR_002560](https://scicrunch.org/resolver/SCR_002560)) were used in designing the riboprobes.

Quantitative RT-PCR {#s4-5}
-------------------

RNA from zebrafish embryo lysates was isolated using the RNeasy kit (Qiagen - Germany). cDNA was synthesized from 1 µg of total RNA using iScript (Bio-Rad - Hercules, CA). Intron-spanning primers, when possible, were designed using the Universal ProbeLibrary Assay Design Center (Roche Applied Science). A complete list of primer sets is provided in [Supplementary file 5](#SD9-data){ref-type="supplementary-material"}.

PCR master mix was prepared with the FastStart Essential DNA Probe Master kit and Universal ProbeLibrary probes according to the manufacturer's protocols (Roche Applied Science - Germany). PCR was performed in triplicate using the LightCycler 96 System (Roche Applied Science) with 45 cycles of amplification and annealing temperature of 60°C. Fold change in gene expression was measured by normalizing against 18S rRNA and comparing test group with control.

Alcian blue assay {#s4-6}
-----------------

Cartilage of 96 hpf embryos was stained with alcian blue as previously described ([@bib32]). Briefly, embryos were fixed in 4% sucrose-buffered paraformaldehyde, bleached with 30% hydrogen peroxide for 2 hr and stained with alcian blue overnight. The embryos were then cleared in acidic ethanol for 4 hr, dehydrated stepwise in ethanol and stored either in glycerol or 2:1 benzyl benzoate/benzyl alcohol solution. Stained embryos were examined using an Olympus SZX12/DP71 imaging system (Olympus Corporation).

Seahorse bioscience XF assay {#s4-7}
----------------------------

Metabolic respiration in 72 hpf embryos, expressed as oxygen consumption rate (OCR), was measured using XF24 Extracellular Flux Analyzer (Seahorse Bioscience - North Billerica, MA) as previously described ([@bib42]). As a minor modification, mixing step was omitted during measurement cycle. Statistical analyses were performed using unpaired t-test (GraphPad Prism v 7.02, RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)).

Triglyceride (TG) assay {#s4-8}
-----------------------

Embryos were harvested at 72 hpf and homogenized in 0.05% PBST +1X protease inhibitor. TG levels were determined using the Infinity Triglycerides Liquid Stable Reagent (Thermo Scientific - Waltham, MA) by measuring absorbance at 540 nm. Total protein concentration was determined using the DC Protein Assay (Bio-Rad) to normalize TG levels. Statistical analyses were performed using unpaired t-test (GraphPad Prism v 7.02, RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)).

Lactate assay {#s4-9}
-------------

Lactate levels were measured in 72 hpf embryos using the EnzyChrom L-Lactate Assay kit (BioAssay Systems - Hayward, CA) as previously described ([@bib2]). Groups of 25--50 embryos were used in the assay. Statistical analyses were performed using unpaired t-test (GraphPad Prism v 7.02, RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)).

Histological analyses {#s4-10}
---------------------

Embryos were fixed in 10% neutral buffered formalin, dehydrated in 70% ethanol and embedded in paraffin. Five-micron sections were cut using a Shandon Finesse E Microtome (Thermo Scientific) and stained with hematoxylin and eosin (H and E). Sections were analyzed using a Nikon Eclipse 80i/DS-Fi1 imaging system (Nikon Instruments Inc - Japan).

Bioinformatic analyses {#s4-11}
----------------------

Publicly available curated databases and analysis software were utilized to examine mutations and gene expression alterations in APC and pyruvate metabolism enzymes (MPC1, MPC2, CS, PDK1, PDHA1, PC, PKLR, LDHA, SLC16A1,GYS1). COSMIC (<http://cancer.sanger.ac.uk/cosmic>, RRID:[SCR_002260](https://scicrunch.org/resolver/SCR_002260)) was mined for mutations that are found in human cancers ([@bib16]). Polyphen2 (<http://genetics.bwh.harvard.edu/pph2/index.shtml>, RRID:[SCR_008584](https://scicrunch.org/resolver/SCR_008584)) was used to predict functional and structural consequences of amino acid substitutions in proteins mentioned above ([@bib1]).

For *MPC1* expression analysis, Oncomine ([www.oncomine.org](http://www.oncomine.org), RRID:[SCR_010949](https://scicrunch.org/resolver/SCR_010949)) was utilized to determine the colon adenocarcinoma subset (n = 101) in the TCGA (<http://cancergenome.nih.gov>, RRID:[SCR_003193](https://scicrunch.org/resolver/SCR_003193)) colorectal carcinoma sample set (n = 237), which was further selected, using COSMIC, for truncating mutations in APC upstream of codon 1600, encompassing the MCR region (n = 91). *MPC1* expression level in these samples was compared with normal colon (n = 19). Colon mucinous adenocarcinomas (n = 22) within the same TCGA colorectal carcinoma sample set were analyzed for gene expression of pyruvate metabolism genes, with normal colon as control. Statistical analysis was performed using Mann Whitney test (GraphPad Prism v 6.04, RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)).

Oncomine also allowed for gene expression analysis of individual pyruvate metabolism genes (n = 10) and randomly selected Uniprot genes (n = 55) (<http://www.uniprot.org/uniprot/?query=reviewed:yes+AND+organism:9606&random=yes>, RRID:[SCR_002380](https://scicrunch.org/resolver/SCR_002380)) in multiple cancer types employing these thresholds: *p value* = 0.001; *fold-change* = 1.5; *gene rank* = top 10%; *data type* = all. A plot was generated to show percentage of datasets meeting set thresholds with respect to total unique analyses for each gene tested in both groups. Statistical analysis was performed using unpaired t-test (GraphPad Prism v 6.04, RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)).

Overall survival in 21 different TCGA cancer types, segregated by presence of mutations in pyruvate metabolism genes, was analyzed with cBioportal (<http://www.cbioportal.org/index.do>, RRID:[SCR_014555](https://scicrunch.org/resolver/SCR_014555)) ([@bib6]). To verify the specificity of our pyruvate metabolism gene set as predictor of overall survival, four groups of ten random genes from Uniprot were utilized as a negative control gene set.

Statistical analyses {#s4-12}
--------------------

Unpaired t-test was used to compare two unmatched, independent groups. Fisher's exact test was used to determine if outcome is related to a categorical condition by more than chance. Mann-Whitney test was used to compare distribution of two unmatched groups. For fold change data, statistical significance was determined from t-test analyses of relative gene expression. For sample size calculations, the minimum number of samples per group (95% power) was determined by assuming the probability of the defect in the control group is 5% or lower and 80% in the experimental group.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"A metabolic switch controls intestinal differentiation downstream of Adenomatous Polyposis Coli (APC)\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Robb Krumlauf as the Senior Editor and Reviewing Editor. The following individual involved in review of your submission has agreed to reveal their identity: Linheng Li (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This is an interesting study, using zebrafish as a model, that describes a link between APC and MPC1 expression in the differentiating gut. The data suggests that APC controls the level of MPC1 through the retinoic acid pathway and shows that knockdown of MPC1 recapitulated phenotypes of impaired APC function including failed intestinal differentiation during development. The study provides insight into the role of APC in regulating pyruvate metabolism in intestinal development. Furthermore, these results may be informative for some of the metabolic effects observed on loss of APC in colon cancer. However, there are a number of concerns that need to be addressed to properly support the conclusions made in the paper and facilitate further consideration for publication in *eLife*.

1\) The authors observe that the expression level of several enzymes in the pyruvate pathway are reduced in Apc^mcr^ zebrafish, while the expression levels of the same enzymes increase in MPC1 MO model. This observation raises a question of whether the similar phenotypes of MPC1 KD and APC mutation are the result of effects on the same targets. The authors need to comment on this issue.

2\) It is important to show the phenotypes of overexpression MPC1 by injecting mRNA.

3\) Did the authors observe any metabolic switch? What\'s the change of glycolysis and fatty acid metabolism in Apc^mcr^ and MPC1 KD intestines?

4\) In [Figure 4](#fig4){ref-type="fig"}, the authors show that both APC mutant and MPC1 knockdown zebrafish display reduced OCR. To more rigorously claim that impaired mitochondrial function (OCR) in APC mutants is mediated by reduced MPC1 expression, they could show that OCR is rescued in APC mutants when MPC1 is overexpressed (as they did in [Figure 3](#fig3){ref-type="fig"}).

5\) If both APC and MPC1 knockdown lead to defects in mitochondrial function, can they reconcile the gene expression differences in TCA cycle enzymes observed with MPC1 knockdown versus APC mutants ([Figure 4](#fig4){ref-type="fig"} vs. [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"})?

6\) An important control is missing to determine whether MPC2 depletion affects MPC1 expression and vice versa.

7\) The authors suggest that retinoic acid modulates MPC1 expression yet show little evidence besides gene expression changes to connect retinoic acid to APC and MPC1. This could be very indirect. Are retinoic acid levels decreased in APC mutants? Are metabolic defects (OCR) observed in APC mutants rescued by exogenous retinoic acid? The evidence involving retinoic acid is not very strong.

10.7554/eLife.22706.025

Author response

\[...\] 1) The authors observe that the expression level of several enzymes in the pyruvate pathway are reduced in Apc^mcr^ zebrafish, while the expression levels of the same enzymes increase in MPC1 MO model. This observation raises a question of whether the similar phenotypes of MPC1 KD and APC mutation are the result of effects on the same targets. The authors need to comment on this issue.

We agree this needs discussion and have revised the text to point out that APC has multiple functions. In addition, regulation of the various enzymes downstream of APC could occur in parallel with regulation of MPC1. If this were the case, then knockdown of MPC1 would not necessarily result in changes of the other enzymes. The observed difference, as pointed out by the reviewers, suggests this to be the case.

2\) It is important to show the phenotypes of overexpression MPC1 by injecting mRNA.

We agree and have provided this as new data in the manuscript ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}).

3\) Did the authors observe any metabolic switch? What\'s the change of glycolysis and fatty acid metabolism in Apc^mcr^ and MPC1 KD intestines?

We have observed reduced mitochondrial oxidation and lower triglyceride levels in apc mutants, apc morphants and mpc1 morphants ([Figure 4A, B](#fig4){ref-type="fig"}). As an extension, we have also shown that lactate levels are up in apc mutants ([Figure 4E](#fig4){ref-type="fig"}). We have documented changes in MPC1 levels directly in the intestine by in situ hybridization and observed an intestinal-specific phenotype by knockdown of MPC1 ([Figure 1C, 1D](#fig1){ref-type="fig"}, [2B, 2C](#fig2){ref-type="fig"}).

4\) In [Figure 4](#fig4){ref-type="fig"}, the authors show that both APC mutant and MPC1 knockdown zebrafish display reduced OCR. To more rigorously claim that impaired mitochondrial function (OCR) in APC mutants is mediated by reduced MPC1 expression, they could show that OCR is rescued in APC mutants when MPC1 is overexpressed (as they did in [Figure 3](#fig3){ref-type="fig"}).

We have performed the requested rescue experiment and have shown that lactate levels are significantly reduced in apc mutants overexpressing MPC1 ([Figure 4E](#fig4){ref-type="fig"}). We used lactate as a second marker for increased anaerobic glycolysis. This again is consistent with a role for MPC1 downstream of APC.

5\) If both APC and MPC1 knockdown lead to defects in mitochondrial function, can they reconcile the gene expression differences in TCA cycle enzymes observed with MPC1 knockdown versus APC mutants ([Figure 4](#fig4){ref-type="fig"} vs. [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"})?

This is a similar point as number \#1 above. Although we think MPC1 and other TCA cycle enzymes are downstream of APC, our data suggest that they are regulated in parallel. MPC1 knockdown alone does not therefore, recapitulate this result.

6\) An important control is missing to determine whether MPC2 depletion affects MPC1 expression and vice versa.

We have done this experiment and knockout of MPC2 does not affect levels of MPC1 ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}).

7\) The authors suggest that retinoic acid modulates MPC1 expression yet show little evidence besides gene expression changes to connect retinoic acid to APC and MPC1. This could be very indirect. Are retinoic acid levels decreased in APC mutants? Are metabolic defects (OCR) observed in APC mutants rescued by exogenous retinoic acid? The evidence involving retinoic acid is not very strong.

A major focus of our lab over the past 12 years is the role of retinoic acid downstream of APC in each of the phenotypes described here (Jette 2004, Nadauld 2004, Nadauld 2005, Nadauld 2006, Rai 2010). Our findings are documented in 12 published manuscripts that illustrated that many of the defects in apc mutant fish, including intestinal differentiation, result from the lack of RA synthesis. This process is controlled mechanistically by CTBP1. We have revised the text to make this point more clear. Although we have firmly established an epistatic role for RA downstream of APC in our previous work, the specific direct functions of RA remain unclear. Our key recent finding suggests that RA effects are indeed indirect by controlling the remodeling of the epigenetic landscape to allow differentiation (Rai 2010). Here we are demonstrating again an epistatic relationship of MPC1 downstream of RA. We have now addressed the direct versus indirect question raised by the reviewers by treating 72 hpf apc mutants with RA. At this time point, we do not observe an immediate induction of MPC1. RA rescue experiments are difficult to perform as RA itself has a profound effect on the development of the embryo overall. We, therefore, rely on RA deficiency experiments to place MPC1 downstream of RA. In this case, blockade of RA synthesis caused phenotypes similar to loss of APC and leads to reduced levels of MPC1. We have revised the manuscript to emphasize the likely indirect regulation of MPC1 by RA.
